Akoya BioSciences
AKYA

$2.46

0.82%

Market Cap: 121M

About: Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

Employees: 330

Industrials Laboratory Analytical Instruments

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

5% more funds holding

Funds holding: 65 [Q4 2023] → 68 (+3) [Q1 2024]

0.16% more ownership

Funds ownership: 30.07% [Q4 2023] → 30.23% (+0.16%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

13% less capital invested

Capital invested by funds: $80.1M [Q4 2023] → $69.7M (-$10.4M) [Q1 2024]

26% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 23

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$4

63%

upside

Avg. target

$7.25

195%

upside

High target

$10

307%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Morgan Stanley Tejas Savant	63%upside $4	Overweight Maintained	3 Jun 2024
Canaccord Genuity Kyle Mikson	144%upside $6	Buy Maintained	14 May 2024
BTIG Mark Massaro	144%upside $6	Buy Maintained	14 May 2024
JP Morgan Rachel Vatnsdal	307%upside $10	Overweight Maintained	6 Mar 2024
UBS John Sourbeer	205%upside $7.5	Buy Maintained	5 Mar 2024

See Analyst Rankings

Financial journalist opinion

Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences

MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences

Lab Instrument Industry Update - New Commercial Entrants

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.

Lab Instrument Industry Update - New Commercial Entrants

Akoya Biosciences, Inc. (AKYA) Q1 2024 Earnings Call Transcript

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Kyle Mikson - Canaccord David Westenberg - Piper Sandler Mark Massaro - BTIG Tejas Savant - Morgan Stanley Subhalaxmi Nambi - Guggenheim Rachel Vatnsdal - JP Morgan Mason Carrico - Stephens Timothy Chiang - Capital One Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences First Quarter 2024 Earnings Conference Call.

Akoya Biosciences, Inc. (AKYA) Q1 2024 Earnings Call Transcript

Zacks Investment Research

Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.49 per share a year ago.

Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates

Akoya Biosciences Reports First Quarter 2024 Financial Results

MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024.

Akoya Biosciences Reports First Quarter 2024 Financial Results

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients

Leveraging Akoya's market-leading PhenoImager HT platform and clinical development expertise with NeraCare's Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. Leveraging Akoya's market-leading PhenoImager HT platform and clinical development expertise with NeraCare's Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients.

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients

Zacks Investment Research

Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts

MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company's PhenoCycler®-Fusion and the PhenoImager® HT platforms.

Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts

Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows

MARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket approval from China's National Medical Products Administration (NMPA) to support next generation pathology clinical workflows.

Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows

Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024

MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024

See News Rankings